[go: up one dir, main page]

WO1996013263A3 - Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides - Google Patents

Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides Download PDF

Info

Publication number
WO1996013263A3
WO1996013263A3 PCT/US1995/014070 US9514070W WO9613263A3 WO 1996013263 A3 WO1996013263 A3 WO 1996013263A3 US 9514070 W US9514070 W US 9514070W WO 9613263 A3 WO9613263 A3 WO 9613263A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingolipid biosynthesis
inhibitors
treatment
methods
viral disease
Prior art date
Application number
PCT/US1995/014070
Other languages
English (en)
Other versions
WO1996013263A2 (fr
Inventor
Meir Lev
K Soma Sundaram
Yaffa Mizrachi
Arye Rubinstein
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of WO1996013263A2 publication Critical patent/WO1996013263A2/fr
Publication of WO1996013263A3 publication Critical patent/WO1996013263A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelle méthode d'inhibition de la réplication des virus axée en particulier sur l'utilisation d'un inhibiteur de la biosynthèse des sphingolipides en vue du traitement ou de la prévention d'infections causées par des virus encapsidés dont le VIH. La cyclosérine L est l'inhibiteur préféré de la biosynthèse des sphingolipides. L'invention porte également sur des compositions pharmaceutiques renfermant des inhibiteurs de la biosynthèse des sphingolipides dont la cyclosérine L.
PCT/US1995/014070 1994-11-01 1995-10-30 Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides WO1996013263A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33296994A 1994-11-01 1994-11-01
US08/332,969 1994-11-01

Publications (2)

Publication Number Publication Date
WO1996013263A2 WO1996013263A2 (fr) 1996-05-09
WO1996013263A3 true WO1996013263A3 (fr) 1996-06-13

Family

ID=23300674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014070 WO1996013263A2 (fr) 1994-11-01 1995-10-30 Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides

Country Status (1)

Country Link
WO (1) WO1996013263A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105412A2 (hu) * 1999-01-13 2002-05-29 Jomaa Pharmaka Gmbh. 3-Izoxazolidinon- és karboxi-alkil-hidroxámsav-származékok alkalmazása fertőzések kezelésére szolgáló gyógyszerkészítmények előállítására

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.M.BATES: "HIV medicine: drug side effects and interactions", POSTGRADUATE MEDICAL JOURNAL, vol. 72, no. 843, pages 30 - 36 *
N.G. KASPARYAN: "GLYCOSPHINGOLIPID METABOLISM AND SHEDDING IN NON-TRANSFORMED AND MURINE SARCOMA VIRUS TRANSFORMED METASTATIC VARIANT CELLS", DIALOG(R)FILE 35: DISSERTATION ABSTRACTS ONLINE, ABSTRACT 0978983 *
Y.MIZRACHI ET AL.: "L-Cycloserine, an Inhibitor of Sphingolipid Biosynthesis, Inhibits HIV-1 Cytopathic Effects, Replication, and Infectivity", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 11, no. 2, 1 February 1996 (1996-02-01), pages 137 - 141 *

Also Published As

Publication number Publication date
WO1996013263A2 (fr) 1996-05-09

Similar Documents

Publication Publication Date Title
WO2001090121A3 (fr) Methodes et compositions permettant de traiter le virus de l'hepatite c
EP1340744A3 (fr) Inhibiteurs de la protéase VIH
WO2003026589A3 (fr) Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
WO1996006620A3 (fr) Analogues de lipides pour le traitement d'infections virales
WO2001060315A3 (fr) Methode de traitement ou de prevention d'infections a flavivirus a l'aide d'analogues nucleosidiques
CA2075173A1 (fr) Composes et methodes pour inhiber le vih et les virus associes
NZ515392A (en) Respiratory syncytial virus replication inhibitors
CA2163456A1 (fr) Nouvelle methode pour bloquer la replication de virus dependant de transcriptases inverses grace a des inhibiteurs de la synthese de desoxynucleotides
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
MXPA03002022A (es) Conjugados de inhibidor de neuraminidas multivalentes.
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
BG102106A (en) Phermaceutical composition containing proteinase inhibitor and monoglyceride
WO2004085682A3 (fr) Utilisation de substances actives pour la prevention ou le traitement de maladies virales, et systeme de test pour la recherche de telles substances actives
ZA991029B (en) Composition and methods for treatment of hiv infections.
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
CA2100066A1 (fr) Michellamines utilisees comme agents antiviraux, composition et methode de traitement
WO1996013263A3 (fr) Methodes de traitement de maladies virales par des inhibiteurs de la biosynthese des sphingolipides
WO2001010454A3 (fr) Composition et procedes de traitement d'infection par le vih
WO1996000068A3 (fr) Therapie combinee contre les infections a vih
WO2002010124A3 (fr) Sels d'un inhibiteur de la protease du vih
WO1998040357A3 (fr) Inhibiteurs de la protease du vih
WO2002006190A3 (fr) Formes cristallines et salines d'un inhibiteur de protease du vih
WO2003093415A3 (fr) Methodes utilisees dans le traitement et la prevention d'une infection par vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase